BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Day In Review: Encysive Pharmaceuticals (ENCY) Re-Submits Thelin


5/25/2006 6:19:49 PM

May 25, 2006 – Encysive responded to the approvable letter it received for Thelin, without needing additional trials; Genentech requested FDA approval of Avastin as a first-line therapy for breast cancer; Allergan received European approval of Ganfort as a glaucoma therapy; Angiotech Pharma will acquire Quill Medical for $40 million; SciClone said Zadaxin failed a Phase III trial against hepatitis C; Adams Respiratory bought Delsym, a prescription 12-hour cough syrup, from UCB for $122 million; New River Pharma presented data showing its attention deficit disorder drug was effective in children between the ages of 6 and 12; Trinity Biotech will buy the coagulation product line from bioMerieux for $51.9 million; and Volcano, which makes intravascular ultrasound imaging devices, set terms for its IPO. The Centient Biotech 200™ moved up 66 points to 3642.10, a rise of 1.84%. More details...


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES